Investor Presentaiton
FORMULATION FACILITIES
INTERNATIONAL MARKETS
DOMESTIC MARKETS
NATCO PHARMA LTD
NATCO
KOTHUR
TELANGANA
Oral and solid dosages including
dry powder, cytotoxic & non-
cytotoxic orals and cytotoxic
injectables.
USFDA, GMP, DCA, German
Health Authority, Australia TGA,
ANVISA (Brazil)
USFDA audit conducted in
October 2023, received Form
483, awaiting EIR
VISAKAPATNAM
ANDHRA PRADESH
Solid oral tablet and capsule
manufacturing
Site approval received from
USFDA. ANVISA, Health Canada
Authority
Located in a Special Economic
Zone (SEZ)
USFDA audit with Establishment
Inspection Report (EIR) received
in June 2023
NAGARJUNASAGAR
TELANGANA
GUWAHATI
ASSAM
Oncology, Antibiotics and
Antiviral
Tablets, Capsules
ANVISA (Brazil), WHO GMP and
Kenya MOH, EFMHACA-
Ethiopia, NMRA- Sri Lanka,
Health Canada
Approvals in place to service
regulatory markets
WHO-GMP, CDSCO Compliant
facility
DEHRADUN
UTTARAKHAND
Tablets, Capsules
GMP, WHO-GMP, Public Health
Service of the Netherlands (EU
GMP)
10View entire presentation